As of May 29
| +0.92 / +7.16%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 38.00, with a high estimate of 50.00 and a low estimate of 30.00. The median estimate represents a +175.96% increase from the last price of 13.77.
The current consensus among 6 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.